
Pro Medicus Ltd
ASX:PME

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
123
317.69
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
PME
stock under the Base Case scenario is
28.06
AUD.
Compared to the current market price of 317.34 AUD,
Pro Medicus Ltd
is
Overvalued by 91%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Pro Medicus Ltd
Loading...
US |
![]() |
Veeva Systems Inc
NYSE:VEEV
|
|
US |
C
|
Cerner Corp
LSE:0R00
|
|
US |
![]() |
Doximity Inc
NYSE:DOCS
|
|
JP |
![]() |
M3 Inc
TSE:2413
|
|
SE |
![]() |
Sectra AB
STO:SECT B
|
|
US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
|
US |
![]() |
Inspire Medical Systems Inc
NYSE:INSP
|
|
CN |
![]() |
Winning Health Technology Group Co Ltd
SZSE:300253
|
|
IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
|
US |
V
|
Vocera Communications Inc
F:V00
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Heightened competition from larger healthcare IT players could erode Pro Medicus’s pricing power and disrupt its pipeline of long-term contracts, especially in the heavily contested U.S. hospital market.
Reliance on a few marquee contracts, including sizeable deals with major hospital networks, poses revenue-concentration risk. Any failure to renew or expand these key partnerships could materially impact the firm’s top line.
Regulatory hurdles and prolonged sales cycles in new geographic regions could delay client onboarding, driving up costs and extending the time needed to realize meaningful returns on international expansion initiatives.
Pro Medicus’s cloud-based imaging software offers faster performance and greater scalability than most legacy systems, giving it a strong competitive advantage in winning high-margin, multi-year contracts with top-tier healthcare providers.
The company has demonstrated consistent growth in recurring revenue tied to usage-based licensing fees, reflecting robust adoption rates and strong stickiness among its existing hospital networks in the U.S. and Europe.
An agile research and development approach, supported by a debt-free balance sheet, enables Pro Medicus to quickly incorporate emerging technologies like AI-driven analytics, expanding its service offerings and creating additional revenue streams.

Revenue & Expenses Breakdown
Pro Medicus Ltd
Balance Sheet Decomposition
Pro Medicus Ltd
Current Assets | 239.4m |
Cash & Short-Term Investments | 182.3m |
Receivables | 54.3m |
Other Current Assets | 2.8m |
Non-Current Assets | 54.8m |
Long-Term Investments | 7.3m |
PP&E | 2.2m |
Intangibles | 21.1m |
Other Non-Current Assets | 24.2m |
Current Liabilities | 34m |
Accounts Payable | 575k |
Other Current Liabilities | 33.4m |
Non-Current Liabilities | 37.9m |
Long-Term Debt | 1.2m |
Other Non-Current Liabilities | 36.7m |
Free Cash Flow Analysis
Pro Medicus Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Pro Medicus Ltd
Revenue
|
190.9m
AUD
|
Cost of Revenue
|
-281k
AUD
|
Gross Profit
|
190.6m
AUD
|
Operating Expenses
|
-50.9m
AUD
|
Operating Income
|
139.7m
AUD
|
Other Expenses
|
-41.4m
AUD
|
Net Income
|
98.3m
AUD
|
PME Profitability Score
Profitability Due Diligence
Pro Medicus Ltd's profitability score is 88/100. The higher the profitability score, the more profitable the company is.

Score
Pro Medicus Ltd's profitability score is 88/100. The higher the profitability score, the more profitable the company is.
PME Solvency Score
Solvency Due Diligence
Pro Medicus Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Score
Pro Medicus Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PME Price Targets Summary
Pro Medicus Ltd
According to Wall Street analysts, the average 1-year price target for
PME
is 267.11 AUD
with a low forecast of 166.65 AUD and a high forecast of 325.5 AUD.
Dividends
Current shareholder yield for PME is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PME
stock under the Base Case scenario is
28.06
AUD.
Compared to the current market price of 317.34 AUD,
Pro Medicus Ltd
is
Overvalued by 91%.